<!DOCTYPE html>
<!-- saved from url=(0063)https://bestpractice.bmj.com/topics/en-gb/3/management-approach -->
<html class="">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <title>New-onset atrial fibrillation - Approach | BMJ Best Practice</title>
      <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
      <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
      <meta name="description" content="Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age and affects almost 5% of the population older than 69 years of age. Causes significant morbidity and mortality including palpitations, dyspnoea, angina, dizziness or syncope, and features of congesti...">
      <meta name="author" content="Arti N. Shah">
      <meta name="author" content="Bharat K. Kantharia">
      <!-- Optimize Page Hiding Snippet --> 
      <!-- <style>.async-hide
         { opacity: 0 !important}
      </style>
      <script async="" src="./3_management_recommendations_files/adrum-ext.0086dbec5e8a6e717bf36d3a06b62042.js"></script><script src="./3_management_recommendations_files/414393182248444" async=""></script><script async="" src="./3_management_recommendations_files/fbevents.js"></script><script type="text/javascript" async="" src="./3_management_recommendations_files/analytics.js"></script><script async="" src="./3_management_recommendations_files/get-loader.js"></script><script type="text/javascript" async="" src="./3_management_recommendations_files/insight.min.js"></script><script type="text/javascript" async="" src="./3_management_recommendations_files/js"></script><script type="text/javascript" async="" src="./3_management_recommendations_files/uwt.js"></script><script type="text/javascript" async="" src="./3_management_recommendations_files/4896.js"></script><script type="text/javascript" async="" src="./3_management_recommendations_files/analytics.js"></script><script async="" src="./3_management_recommendations_files/gtm.js"></script><script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function()
         {s.className=s.className.replace(RegExp(' ?'+y),'')}
         ; (a[n]=a[n]||[]).hide=h;setTimeout(function()
         
         {i();h.end=null}
         ,c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',3000,
         
         {'GTM-K3TZ3JV':true}
         );
      </script> -->
      <!-- end Optimize Page Hiding Snippet -->
      <!-- Google Tag Manager -->
      <script>
         /*<![CDATA[*/
         
          
         window.dataLayer = window.dataLayer || [];
         window.dataLayer.push({
                    'icsId': null,
                    'pi_icsId': "id82087",
                    'pi_icsName': "BMJ Group (Online access from BMA House)",
                    'access_rights': true,
                    'ics_groupings': [{"name":"Country Grouping"}],
                    'ics_countryName': "GB and ROW",
                    'siteLanguage': "en-gb",
                    'contentLanguage': "en-gb"
                 });
         		  
         /*]]>*/
            
      </script>
      <script>
         (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
         new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
         j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
         'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
         })(window,document,'script','dataLayer', 'GTM-K3TZ3JV');
      </script>
      <!-- End Google Tag Manager -->
      <!-- /* if user in China */ -->
      <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
      <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">
      <link rel="canonical" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach">
      <link rel="alternate" hreflang="uk-ua" href="https://bestpractice.bmj.com/topics/uk-ua/3/management-approach">
      <link rel="alternate" hreflang="en-ie" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach">
      <link rel="alternate" hreflang="az-az" href="https://bestpractice.bmj.com/topics/az-az/3/management-approach">
      <link rel="alternate" hreflang="ru" href="https://bestpractice.bmj.com/topics/ru-ru/3/management-approach">
      <link rel="alternate" hreflang="en-us" href="https://bestpractice.bmj.com/topics/en-us/3/management-approach">
      <link rel="alternate" hreflang="pt" href="https://bestpractice.bmj.com/topics/pt-br/3/management-approach">
      <link rel="alternate" hreflang="ka-ge" href="https://bestpractice.bmj.com/topics/ka-ge/3/management-approach">
      <link rel="alternate" hreflang="pt-br" href="https://bestpractice.bmj.com/topics/pt-br/3/management-approach">
      <link rel="alternate" hreflang="en" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach">
      <link rel="alternate" hreflang="es-es" href="https://bestpractice.bmj.com/topics/es-es/3/management-approach">
      <link rel="alternate" hreflang="zh-cn" href="https://bestpractice.bmj.com/topics/zh-cn/3/management-approach">
      <link rel="alternate" hreflang="es" href="https://bestpractice.bmj.com/topics/es-es/3/management-approach">
      <link rel="alternate" hreflang="zh" href="https://bestpractice.bmj.com/topics/zh-cn/3/management-approach">
      <link rel="alternate" hreflang="x-default" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach">
      <link rel="alternate" hreflang="ru-ru" href="https://bestpractice.bmj.com/topics/ru-ru/3/management-approach">
      <link rel="alternate" hreflang="vi" href="https://bestpractice.bmj.com/topics/vi-vn/3/management-approach">
      <link rel="alternate" hreflang="uk" href="https://bestpractice.bmj.com/topics/uk-ua/3/management-approach">
      <link rel="alternate" hreflang="ka" href="https://bestpractice.bmj.com/topics/ka-ge/3/management-approach">
      <link rel="alternate" hreflang="az" href="https://bestpractice.bmj.com/topics/az-az/3/management-approach">
      <link rel="alternate" hreflang="vi-vn" href="https://bestpractice.bmj.com/topics/vi-vn/3/management-approach">
      <link rel="alternate" hreflang="en-gb" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach">
      <!--[if lte IE 9]>
      <link rel="stylesheet" type="text/css" media="screen" href="/gzip_1791a8687c5480ce19e791d0825e7a6b/css/lte-ie-9.css" >
      <![endif]-->
      <script>
         /*<![CDATA[*/
           var appdynamics_app_key="AD-AAB-AAF-RGR";
         /*]]>*/
           	window["adrum-app-key"] = appdynamics_app_key;
           	window['adrum-start-time'] = new Date().getTime();
           
      </script>
      <script type="text/javascript" src="../js/appdynamics.js"></script>
      <script type="application/ld+json">
         [
         
         { "@context": "http://schema.org", "@type": "MedicalCondition" }
         ,{
         "isAccessibleForFree": "False",
         "hasPart":
         
         { "@type": "WebPageElement", "isAccessibleForFree": "False", "cssSelector" : ".gpw" }
         }]
      </script>
      <meta name="msvalidate.01" content="76FD53F39FDFB050A93D7925608BA016">
      <style type="text/css">._6772342E312E39_src-lib-Adapter-styles__centerStyle--2U8wI, ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M, ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio, ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         top: 50%;
         position: absolute;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         box-sizing: border-box;
         padding: 0;
         border-radius: 3px;
         position: fixed;
         display: block;
         visibility: visible;
         bottom: 0;
         background-color: #f3f3f3;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, -webkit-transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out, -webkit-transform 0.1s 0s ease-in-out;
         z-index: 99999;
         box-shadow: 0px 0px 5px 1px rgba(0, 0, 0, 0.18);
         overflow: hidden;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dragging--2uZno {
         transition: opacity 0.1s 0s linear;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__closed--eHbpJ {
         visibility: hidden;
         opacity: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__loading--1ewAG {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         position: relative;
         height: 35px;
         line-height: 35px;
         min-width: 165px;
         text-align: center;
         cursor: move;
         z-index: 11;
         overflow: hidden;
         font-family: Helvetica;
         font-weight: normal;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         cursor: ew-resize;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         left: 50%;
         height: 16px;
         width: 100px;
         margin-top: -8px;
         margin-left: -50px;
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 20px;
         height: 14px;
         width: 14px;
         border-radius: 8px;
         margin-top: -7px;
         display: none;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__dropdownPresence--18mrh {
         display: none;
         position: absolute;
         width: 100%;
         height: 100vh;
         }
         ._6772342E312E39_src-lib-Adapter-styles__showDropdown--242EQ {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj {
         padding: 10px 15px;
         display: block;
         cursor: pointer;
         text-decoration: none;
         text-align: left;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj:hover {
         background-color: #f5f5f5;
         }
         ._6772342E312E39_src-lib-Adapter-styles__selected--1z5-3 {
         color: #0684bd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM {
         position: relative;
         width: 160px;
         min-width: 165px;
         left: 5px;
         padding: 0;
         min-height: 30px;
         box-sizing: border-box;
         box-shadow: 0 0 4px 0 rgba(0, 0, 0, 0.2);
         background-color: #ffffff;
         border-style: solid;
         border-width: 0;
         border-top-width: 1px;
         border-bottom-width: 0px;
         border-color: #eeeeee;
         border-radius: 4px;
         font-family: "Helvetica Neue", Helvetica, Arial, sans-serif;
         font-size: 14px;
         color: #2F2F2F;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__horizontal--1DydQ {
         display: inline-flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__clickable--G0zEI {
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__noborder--1ysDv {
         border: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 10px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Offline--3PnxB {
         display: block;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Busy--IDedL {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Available--2GLYE {
         display: block;
         background-color: #32ae31;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: none;
         position: absolute;
         width: 8px;
         height: 2px;
         border-radius: 1.5px;
         background-color: #ffffff;
         -webkit-transform-origin: 50% 50%;
         transform-origin: 50% 50%;
         -webkit-transform: translate(3px, 6px);
         transform: translate(3px, 6px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__statusIcon--2SoFd {
         display: inline-block;
         position: relative;
         margin-right: 5px;
         top: 2px;
         left: 0;
         margin-top: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         box-sizing: border-box;
         height: 20px;
         width: 20px;
         margin-top: -12px;
         border-radius: 3px;
         cursor: pointer;
         border-style: solid;
         border-width: 1px;
         border-color: transparent;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw:hover {
         border-color: #cccccc;
         }
         ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 40px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         position: absolute;
         box-sizing: border-box;
         left: 3px;
         bottom: 7px;
         width: 12px;
         height: 2px;
         border: 1px solid #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         height: 12px;
         bottom: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIconBar--2WYhn {
         width: 100%;
         height: 1px;
         background-color: #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR {
         position: relative;
         overflow: hidden;
         margin: 2px;
         width: 14px;
         height: 14px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child, ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         position: absolute;
         height: 2px;
         width: 100%;
         top: 6px;
         left: 0;
         background: #888888;
         border-radius: 1px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child {
         -webkit-transform: rotate(45deg);
         transform: rotate(45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         -webkit-transform: rotate(-45deg);
         transform: rotate(-45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__contentFrame--Z6dLx {
         display: block;
         border: none;
         width: 0;
         height: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.1s 0s ease-in-out, height 0.1s 0s ease-in-out;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__ringing--2c7d0 {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         -webkit-animation-duration: 2s;
         animation-duration: 2s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: infinite;
         animation-iteration-count: infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 33px;
         margin-left: -60px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 100px;
         margin-left: -100px;
         text-overflow: ellipsis;
         overflow: hidden;
         text-align: center;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__center--3fFya, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -50px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #5FB95C;
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX:hover {
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         margin-left: -80px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #FF8800;
         color: #FF8800;
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL:hover {
         color: #FF8800;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__detectNew--2RyZg {
         background: url("https://rc-hack-new.detect");
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         top: initial !important;
         width: 300px;
         border-top-right-radius: 0;
         border-bottom-right-radius: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg {
         width: 60px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         width: 35px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         opacity: 0 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__expandable--1dLZX {
         width: 140px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         line-height: initial;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         width: 12px;
         height: 12px;
         margin-top: -6px;
         z-index: 2;
         transition: .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         -webkit-transform: translate(2px, 5px);
         transform: translate(2px, 5px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         opacity: 0;
         transition: opacity .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         z-index: 2147483648;
         top: 7px;
         position: absolute;
         left: 30px;
         height: 22px;
         width: 22px;
         display: block;
         cursor: pointer;
         opacity: 1;
         transition: .3s;
         display: flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv ._6772342E312E39_src-lib-Adapter-styles__icon--2I9x4 {
         width: 22px;
         height: 22px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         left: 7px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.2s 0s ease-in-out, height 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOutIcon--oudoy img {
         position: absolute;
         top: 3px;
         left: 1px;
         width: 14px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         display: none;
         height: 30px;
         left: 0;
         position: fixed;
         top: 0;
         -webkit-transform: opacity 0.1s 0s linear;
         transform: opacity 0.1s 0s linear;
         z-index: 999999999;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         background-color: rgba(255, 255, 255, 0.95);
         box-sizing: border-box;
         border: 1px solid #cfcfcf;
         border-radius: 4px;
         font-size: 0px;
         height: 30px;
         white-space: nowrap;
         margin: 0 0 0 5px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 img {
         vertical-align: baseline !important;
         display: inline-block !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         margin: 0 5px 0 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #cfcfcf;
         top: calc(50% - 5px);
         left: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #FF8800;
         top: calc(50% - 5px);
         left: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         border-right: none;
         border-left: 5px solid #cfcfcf;
         left: initial;
         right: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         border-right: none;
         border-left: 5px solid #fff;
         left: initial;
         right: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU {
         height: 30px;
         width: 30px;
         margin: -1px 0 0 -1px;
         vertical-align: baseline;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: none;
         position: relative;
         vertical-align: top;
         cursor: pointer;
         font-size: 18px;
         height: 28px;
         width: 28px;
         line-height: 28px;
         text-align: center;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 {
         display: none;
         width: 1px;
         height: 19px;
         margin: 5px 0;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__hack--5AVJK {
         background: url("https://rc-hack-c2d.detect");
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg {
         position: absolute;
         top: 50%;
         left: 50%;
         -webkit-transform: translateX(-50%) translateY(-50%);
         transform: translateX(-50%) translateY(-50%);
         overflow: visible !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg > path {
         fill: #0684bd;
         stroke: #0684bd;
         }
      </style>
      <style type="text/css">add-meeting-button {
         line-height: 36px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__root--3CtVK {
         margin-left: 8px;
         position: relative;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q {
         min-width: 94px;
         white-space: nowrap;
         height: 26px;
         line-height: 26px;
         padding: 0;
         font-size: 11px;
         font-weight: 500;
         text-align: center;
         color: #0684bd;
         background: #fff;
         border-radius: 20px;
         border: 1px solid #9bcee5;
         font-family: Roboto, Helvetica, Arial, sans-serif;
         font-weight: 400;
         outline: none;
         cursor: pointer;
         transition: .3s;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q:hover {
         color: #fff;
         background-color: #9bcee5;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1 {
         color: #fff;
         background-color: #c7c7c7;
         border: 1px solid #c7c7c7;
         cursor: default;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1:hover {
         cursor: default;
         background-color: #c7c7c7;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__or--Hsdgj {
         float: left;
         margin-left: 10px;
         font-size: 12px;
         color: #0684bd;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__icon--r7sAL {
         left: 5px;
         top: 4px;
         width: 18px;
         height: 18px;
         position: absolute;
         background: #fff;
         border-radius: 100%;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__text--1nLnV {
         width: 100%;
         margin-left: 25px;
         padding-right: 6px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__meetingContainer--24va2 {
         display: flex;
         flex-grow: 100;
         align-items: center;
         }
      </style>
      <style type="text/css">#rc-meeting-popup-window {
         width: 100%;
         height: 100%;
         background-color: rgba(0, 0, 0, 0.3);
         display: flex;
         justify-content: center;
         align-items: center;
         line-height: normal;
         text-align: left;
         position: fixed;
         z-index: 2147483647;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__container--2qd2O {
         width: 470px;
         height: auto;
         display: flex;
         flex-direction: column;
         align-items: stretch;
         overflow: hidden;
         box-shadow: 0 24px 38px 3px rgba(0, 0, 0, 0.14), 0 9px 46px 8px rgba(0, 0, 0, 0.12), 0 11px 15px -7px rgba(0, 0, 0, 0.2);
         border-radius: 2px;
         position: relative;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA {
         position: relative;
         width: 100%;
         height: 30px;
         line-height: 30px;
         font-size: 12px;
         box-sizing: border-box;
         background: #ffffff;
         padding-left: 15px;
         padding-top: 10px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__recurringMeetingPrompt--3U97a {
         margin: 5px 22px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X {
         position: absolute;
         top: 13px;
         right: 15px;
         color: rgba(0, 0, 0, 0.54);
         fill: rgba(0, 0, 0, 0.54);
         width: 20px;
         height: 20px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X svg {
         width: 20px;
         height: 20px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__wrapper--3DttD {
         background-color: #ffffff;
         width: 100%;
         padding: 10px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settings--15yhX {
         border-radius: 3px;
         box-sizing: border-box;
         padding: 0 8px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryLabel--2n8iQ {
         margin: 10px 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryWrapper--2LA96 {
         border-radius: 3px;
         background-color: #F9F9F9;
         border: 1px solid #E2E2E2;
         padding: 9px 16px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settingLabel--ybCle {
         display: inline-block;
         width: 80px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF {
         line-height: 20px;
         margin: 7px 0;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF * {
         vertical-align: middle;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__video--1oJss {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__audio--2dr2m {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF input:first-of-type {
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__controls--1GgrW {
         margin: 10px 0 10px 10px;
         height: 30px;
         line-height: 30px;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__schedule--3SMpg {
         background: #4285f4;
         color: #fff;
         transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
         box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14), 0 3px 1px -2px rgba(0, 0, 0, 0.12), 0 1px 5px 0 rgba(0, 0, 0, 0.2);
         border: 0;
         border-radius: 3px;
         cursor: pointer;
         display: inline-block;
         font-weight: 500;
         outline: none;
         overflow: hidden;
         text-align: center;
         z-index: 0;
         font-size: 12px;
         line-height: 30px;
         height: 32px;
         min-width: 88px;
         position: absolute;
         right: 18px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA span {
         font-size: 16px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__password--3Ij_s {
         display: none;
         margin-left: 10px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__spinner--18fX2 {
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         ._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__path--2xqMm {
         stroke-dasharray: 187;
         stroke-dashoffset: 0;
         -webkit-transform-origin: center;
         transform-origin: center;
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
      </style>
      <style></style>
   </head>
   <body class="gpw">
      <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc" class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 " style="">
         <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our 
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link" href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
         <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0" class="cc-btn cc-dismiss">OK!</a></div>
         <!--googleon: all-->
      </div>
      <!-- Google Tag Manager (noscript) -->
      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <!-- End Google Tag Manager (noscript) -->
      <!-- /* if user in China */ -->
      <header id="header" role="banner">
         <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#sr-content">Skip to main content</a>
         <div class="bg-info text-white">
         </div>
         <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
            <div class="container">
               <a href="https://bestpractice.bmj.com/" class="mobLogo"><span class="remove"><abbr>BMJ</abbr> Best Practice</span></a>
               <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
               </button>
               <div id="navbarNav" class="collapse navbar-collapse">
                  <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                     <li id="globalNav-access" class="nav-item" role="presentation">
                        <span class="nav-link"> 
                        Access provided by: 
                        BMJ Group (Online access from BMA House)
                        </span>
                     </li>
                     <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 
                        Help <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink02">
                           <span class="material-icons"></span>
                           <ul role="menu">
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></li>
                           </ul>
                        </div>
                     </li>
                     <li id="globalNav-register" class="nav-item">
                        <a href="https://bestpractice.bmj.com/registration" class="nav-link">Create account</a>
                     </li>
                     <li id="globalNav-login" class="nav-item">
                        <a href="https://bestpractice.bmj.com/login" class="nav-link">Log in</a>
                     </li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
         <div id="mainSearch" class="container">
            <div class="row">
               <div class="col-lg-7">
                  <div class="logo-img"><a href="https://bestpractice.bmj.com/"><span class="remove"><abbr title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
               </div>
               <div class="col-lg-5">
                  <style type="text/css">
                     #searchBoxWrap .tt-open:before {content: "Recently viewed topics:"; }
                     #searchBoxWrap .tt-label-override:before,
                     #searchBoxWrap .tt-suggested:before {content: "Suggested topics:" !important; }
                  </style>
                  <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search" novalidate="novalidate">
                     <div class="input-group">
                        <div id="searchBoxWrap">
                           <label for="q" class="sr-only">Search</label>
                           <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                              <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value="" class="tt-input" autocomplete="off" spellcheck="false" dir="auto" style="position: relative; vertical-align: top;">
                              <pre aria-hidden="true" style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                              <div class="tt-menu" style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                                 <div class="tt-dataset tt-dataset-0"></div>
                              </div>
                           </span>
                           <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                        </div>
                     </div>
                  </form>
                  <script>
                     /*<![CDATA[*/
                     
                            <!-- These are required in completion, see BP-232 -->
                            var searchDefaultLanguageCode = "en-gb";
                            var regionName = "GB and ROW";
                            var regionAvailableLanguagesCodes = [{"id":"1","code":"en-gb","displayName":"English"},{"id":"3","code":"pt-br","displayName":"Portugu\u00EAs"},{"id":"5","code":"es-es","displayName":"Espa\u00F1ol"},{"id":"7","code":"ru-ru","displayName":"\u0420\u0443\u0441\u0441\u043A\u0438\u0439"}];
                            var availableLanguages = [];
                     
                            for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                                availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                            }
                     /*]]>*/
                  </script>
               </div>
            </div>
         </div>
         <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
            <div class="container">
               <div id="mainNavbarNav">
                  <ul class="navbar-nav" role="menubar">
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
      </header>
      <script type="text/javascript" id="">(function(){var f=google_tag_manager["GTM-K3TZ3JV"].macro(4),b=google_tag_manager["GTM-K3TZ3JV"].macro(5),a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};f?"true"!=b&&("justLoggedIn"==b?a("loggedIn","true",2):a("loggedIn","justLoggedIn",2)):a("loggedIn","false",2)})();</script><script type="text/javascript" id="">var meta=document.createElement("meta");meta.name="msvalidate.01";meta.content="76FD53F39FDFB050A93D7925608BA016";document.getElementsByTagName("head")[0].appendChild(meta);</script>
      <main id="tmp" class="container tmp tmp-basic main-container" role="main">
         <script type="text/javascript">
            /*<![CDATA[*/ 
            var topicId = 3; 
            var langCode="en-gb"; 
            /*]]>*/
         </script>
         <div id="topicNav" class="container">
            <div class="lang">
               <ul role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/3" class="active">English</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/pt-br/3">Português</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/es-es/3">Español</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/ru-ru/3">Русский</a></li>
               </ul>
            </div>
            <div id="topicMenuTopBg" style="height: 110px;"></div>
            <div id="topicMenuTopWrap" style="height: 110px;">
               <div id="topicMenuTop" style="height: 110px;">
                  <h1>New-onset atrial fibrillation</h1>
                  <div class="pdf-links-nav">
                     <div class="pdf">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/pdf/3.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                        </a>
                     </div>
                  </div>
                  <div id="mobileMenu" class="mUp">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                     </a>
                  </div>
                  <ul id="menuLinks" role="menu">
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#smenu-0" aria-owns="menu-0">Overview <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#smenu-1" aria-owns="menu-1">Theory <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#smenu-2" aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#smenu-3" aria-owns="menu-3">Management <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#smenu-4" aria-owns="menu-4">Follow up <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#smenu-5" aria-owns="menu-5">Resources <span class="material-icons"></span><span class="material-icons"></span></a></li>
                  </ul>
               </div>
            </div>
            <div id="topicMenuBottomWrap" style="height: 208px;">
               <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 208px;">
                  <ul id="menus" role="menubar">
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" class="parent"><span>Overview</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-0">
                           <li><a href="3_overview_summary.html" id="Summary">Summary</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" class="parent"><span>Theory</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-1">
                           <li><a href="3_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/aetiology" id="Aetiology">Aetiology</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/case-history" id="Case history">Case history</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" class="parent"><span>Diagnosis</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-2">
                           <li><a href="3_diagnosis_recommedations.html" id="Recommendations">Recommendations</a></li>
                           <li><a href="3_diagnosis_history_and_exam.html" id="History and exam">History and exam</a></li>
                           <li><a href="3_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/differentials" id="Differentials">Differentials</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/criteria" id="Criteria">Criteria</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/screening" id="Screening">Screening</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" class="parent"><span>Management</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-3">
                           <li><a href="3_management_recommendations.html" id="Recommendations" class="active">Recommendations</a></li>
                           <li><a href="3_management_treatment_algorithm.html" id="Treatment algorithm">Treatment algorithm</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/prevention" id="Prevention">Prevention</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/patient-discussions" id="Patient discussions">Patient discussions</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" class="parent"><span>Follow up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-4">
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/monitoring" id="Monitoring">Monitoring</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/complications" id="Complications">Complications</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/prognosis" id="Prognosis">Prognosis</a></li>
                        </ul>
                     </li>
                     <li>
                        <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" class="parent"><span>Resources</span><span class="material-icons"></span><span class="material-icons"></span></a>
                        <ul role="menu" id="menu-5">
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/guidelines" id="Guidelines">Guidelines</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/images-and-videos" id="Images and videos">Images and videos</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/references" id="References">References</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/patient-leaflets" id="Patient leaflets">Patient leaflets</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/calculators" id="Calculators">Calculators</a></li>
                           <li><a href="https://bestpractice.bmj.com/topics/en-gb/3/evidence" id="Evidence">Evidence</a></li>
                        </ul>
                     </li>
                     <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/3/pdf/3.pdf" target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span></a></li>
                  </ul>
               </nav>
            </div>
         </div>
         <h2 id="sr-content">Approach</h2>
         <div class="card">
            <div class="card-block">
               <section>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The 3 elements in the management of new-onset AF are:
                     <span class="reference">
                        <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                        <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                           http://content.onlinejacc.org/article.aspx?articleid
                           <rc-c2d-number data-rc-number="=1854231
                              ">=1854231</rc-c2d-number>
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference">
                        <a href="#referencePop34" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[34]</a> 
                        <span class="citationText" aria-hidden="true">
                           Kanji S, Stewart R, Fergusson DA, et al. Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials. Crit Care Med. 2008;36
                           <rc-c2d-number data-rc-number=":1620-1624">:1620-1624</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/18434899?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop35" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[35]</a> 
                     <span class="citationText" aria-hidden="true">Okcun B, Yigit Z, Yildiz A, et al. What should be the primary treatment in atrial fibrillation: ventricular rate control or sinus rhythm control with long-term anticoagulation? J Int Med Res. 2009;37:464-471.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/19383241?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference">
                        <a href="#referencePop36" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[36]</a> 
                        <span class="citationText" aria-hidden="true">
                           Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361
                           <rc-c2d-number data-rc-number=":1139-1151 ">:1139-1151 </rc-c2d-number>
                           (erratum in: N Engl J Med. 2010;363:1877).
                        </span>
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.nejm.org/doi/full/10.1056/NEJMoa0905561#t=article
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19717844?tool=bestpractice.com
                        </span>
                     </span>
                  </p>
                  <ol>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Ventricular rate control
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Restoration and maintenance of sinus rhythm
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Prevention of thromboembolic events.
                        </p>
                     </li>
                  </ol>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Management of new-onset AF depends on the nature of its presentation, so the urgency of the treatment required should be assessed. Most cases of new-onset AF revert to sinus rhythm spontaneously, but do require adequate ventricular rate control with drugs such as beta-blockers, calcium-channel blockers, and occasionally digoxin. Cases that revert spontaneously usually do so in the first 24 hours.
                     <span class="reference"> 
                     <a href="#referencePop4" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[4]</a> 
                     <span class="citationText" aria-hidden="true">Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93(6):1262-77.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circ.ahajournals.org/content/93/6/1262.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/8653857?tool=bestpractice.com
                     </span>
                     </span>
                     Those patients who do not revert may require either direct current (DC) cardioversion or pharmacological cardioversion. Depending on further risks for AF, patients may require treatment with various anti-arrhythmic agents to prevent AF. Among the available anti-arrhythmic agents, dronedarone, a multichannel blocker that inhibits the sodium, potassium, and calcium channels and has non-competitive anti-adrenergic activity similar to sotalol, propafenone, and flecainide, has lower efficacy than amiodarone to maintain sinus rhythm.
                     <span class="reference"> 
                     <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                     <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop38" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[38]</a> 
                     <span class="citationText" aria-hidden="true">Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/20384650?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop39" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[39]</a> 
                     <span class="citationText" aria-hidden="true">Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/19213680?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop40" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[40]</a> 
                     <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Dronedarone for the treatment of non-permanent atrial fibrillation. August 2010. http://www.nice.org.uk (last accessed 8 January 2016).</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://guidance.nice.org.uk/ta197
                     </span>
                     </span>
                     New-onset AF may be the first symptomatic presentation of paroxysmal AF, and it is necessary to perform transoesophageal echocardiography (TOE) to rule out left atrial (LA) clots before cardioversion.
                     <span class="figureWrap">
                     <span class="figure">
                     <span class="figimage">
                     <img class="img-fluid" alt="com.bmj.content.model.Caption@5e9782d2" src="../images/3-6_default.jpg" aria-describedby="img-3-6_default.jpg" data-w="450">
                     </span>
                     <span class="figcaption">
                     <span id="img-3-6_default.jpg">
                     <i class="remove">[Figure caption and citation for the preceding image starts]: </i>
                     <span class="caption">
                     Transoesophageal echocardiogram showing left atrial appendage clot. LA=left atrium; LAA=left atrial appendage; LV=left ventricle.
                     </span>
                     <span class="source">From the collection of Dr Bharat Kantharia</span>
                     <i class="remove"> [Citation ends].</i>
                     </span>
                     </span>
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Many patients require anticoagulation before, during, and after cardioversion to prevent thromboembolic events. Because warfarin takes several days to have a therapeutic effect, patients presenting with new-onset AF treated with warfarin are treated with intravenous heparin (activated partial thromboplastin time [aPTT] of 45-60 seconds) or subcutaneous low molecular weight heparin while they are awaiting cardioversion and being evaluated for long-term anticoagulation.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Several direct oral anticoagulants (DOACs) are approved for stroke prevention in patients with non-valvular AF.
                     <span class="reference"> 
                     <a href="#referencePop41" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[41]</a> 
                     <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. May 2012. http://www.nice.org.uk (last accessed 8 January 2016).</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://guidance.nice.org.uk/TA256
                     </span>
                     </span>
                     These DOACs are non-vitamin K-dependent and they fall into two classes: oral direct thrombin inhibitors and oral direct factor Xa inhibitors.
                     <span class="reference"> 
                     <a href="#referencePop42" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[42]</a> 
                     <span class="citationText" aria-hidden="true">O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012;34:894-901.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22417716?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Dabigatran, an oral direct thrombin inhibitor, was compared with warfarin in the RE-LY trial. In the trial, dabigatran was associated with lower rates of stroke and systemic embolism compared with warfarin but had similar rates of major haemorrhage. At a lower dose of dabigatran, the rates of stroke and systemic embolism were similar to those for warfarin. The rate of MI was higher with both doses of dabigatran than with warfarin.
                     <span class="reference">
                        <a href="#referencePop36" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[36]</a> 
                        <span class="citationText" aria-hidden="true">
                           Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361
                           <rc-c2d-number data-rc-number=":1139-1151 ">:1139-1151 </rc-c2d-number>
                           (erratum in: N Engl J Med. 2010;363:1877).
                        </span>
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.nejm.org/doi/full/10.1056/NEJMoa0905561#t=article
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19717844?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop43" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[43]</a> 
                     <span class="citationText" aria-hidden="true">Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-460.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22537354?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop42" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[42]</a> 
                     <span class="citationText" aria-hidden="true">O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012;34:894-901.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22417716?tool=bestpractice.com
                     </span>
                     </span>
                     Dabigatran may be associated with an increased risk of stroke, heart attack, and blood clot in patients with mechanical prosthetic valves and, therefore, should not be used in these patients.
                     <span class="web-link-wrap"> 
                     <a rel="external" target="_blank" href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm332949.htm">
                     FDA: dabigatran safety alert
                     <span class="icon icon-bp-icons-outbound-link"></span>
                     </a>
                     </span>
                     Based on the current evidence, it is reasonable to use dabigatran as a first-line agent or subsequent replacement for warfarin in suitable patients who do not have marked renal insufficiency, and who do not have mechanical prosthetic valves.
                     <span class="reference"> 
                     <a href="#referencePop43" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[43]</a> 
                     <span class="citationText" aria-hidden="true">Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-460.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22537354?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop42" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[42]</a> 
                     <span class="citationText" aria-hidden="true">O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012;34:894-901.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22417716?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop44" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[44]</a> 
                     <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. March 2012. http://www.nice.org.uk (last accessed 8 January 2016).</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.nice.org.uk/guidance/TA249
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The oral direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban were compared with warfarin for stroke prevention in patients with non-valvular AF in the ROCKET AF trial,
                     <span class="reference"> 
                     <a href="#referencePop45" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[45]</a> 
                     <span class="citationText" aria-hidden="true">Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.nejm.org/doi/full/10.1056/NEJMoa1009638#t=article
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21830957?tool=bestpractice.com
                     </span>
                     </span>
                     ARISTOTLE trial,
                     <span class="reference"> 
                     <a href="#referencePop46" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[46]</a> 
                     <span class="citationText" aria-hidden="true">Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.nejm.org/doi/full/10.1056/NEJMoa1107039#t=article
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21870978?tool=bestpractice.com
                     </span>
                     </span>
                     and the ENGAGE- and ENSURE-AF trials,
                     <span class="reference">
                        <a href="#referencePop47" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[47]</a> 
                        <span class="citationText" aria-hidden="true">
                           Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369
                           <rc-c2d-number data-rc-number=":2093-2104">:2093-2104</rc-c2d-number>
                           .
                        </span>
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.nejm.org/doi/full/10.1056/NEJMoa1310907#t=article
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24251359?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference">
                        <a href="#referencePop48" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[48]</a> 
                        <span class="citationText" aria-hidden="true">
                           Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388
                           <rc-c2d-number data-rc-number=":1995-2003">:1995-2003</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/27590218?tool=bestpractice.com
                        </span>
                     </span>
                     respectively. These trials, together with results from meta-analyses, have shown that DOACs are non-inferior to warfarin for stroke prevention in patients with non-valvular AF.
                     <span class="reference"> 
                     <a href="#referencePop43" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[43]</a> 
                     <span class="citationText" aria-hidden="true">Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-460.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/22537354?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference">
                        <a href="#referencePop49" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[49]</a> 
                        <span class="citationText" aria-hidden="true">
                           Caldeira D, Rodrigues FB, Barra M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015;101
                           <rc-c2d-number data-rc-number=":1204-1211">:1204-1211</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/26037103?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                     [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                     </a>
                     <span class="ccaTitle" aria-hidden="true">How do factor Xa inhibitors compare with warfarin for prevention of cerebral and systemic embolism in people with atrial fibrillation (AF)?</span>
                     <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://www.cochranelibrary.com/cca/doi/10.1002/cca.2101/full</span>
                     <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The efficacy and safety of anticoagulation with warfarin is highly dependent on the quality of anticoagulation control, as reflected by the average time in therapeutic range (TTR) of INR 2 to 3. The SAMe-TT(2)R(2) scoring system (based on sex, age, medical history, treatment interactions, tobacco use, and race) is a tool that may help identify anticoagulation-naive patients who are less likely to maintain TTR &gt;70% and who could, therefore, be managed with DOACs instead of warfarin.
                     <span class="reference">
                        <a href="#referencePop50" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[50]</a> 
                        <span class="citationText" aria-hidden="true">
                           Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014;127
                           <rc-c2d-number data-rc-number=":1083-1088">:1083-1088</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24858062?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference">
                        <a href="#referencePop51" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[51]</a> 
                        <span class="citationText" aria-hidden="true">Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014;146:719-726.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                           http://journal.publications.chestnet.org/article.aspx?articleid
                           <rc-c2d-number data-rc-number="=1860569
                              ">=1860569</rc-c2d-number>
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24722973?tool=bestpractice.com
                        </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The choice of anticoagulation strategy depends on the presentation. Factors in the patient's presentation and diagnostic assessment which guide appropriate treatment include the following:
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Whether the patient is haemodynamically stable or unstable
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           If haemodynamically stable, whether the patient is symptomatic or asymptomatic
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           If symptomatic, the onset of the symptoms (&lt;48 hours, ≥48 hours, or unknown)
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           The presence of associated heart failure
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           The presence of a thrombus on TOE
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           If a thrombus is absent on TOE, thromboembolic risk is stratified.
                           <span class="inlineCalc">
                           <span class="web-link-wrap">
                           <a href="https://bestpractice.bmj.com/calculators/en-gb/AtrialFibCHADSVASc.htm">
                           Atrial Fibrillation CHA(2)DS(2)-VASc Score for Stroke Risk
                           </a>
                           </span>
                           </span>
                        </p>
                     </li>
                  </ul>
               </section>
               <section>
                  <h3>Need for hospital admission</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Patients who present with new-onset AF who are at low risk for major clinical consequences (young patients with no structural heart diseases, no major cardiac symptoms, or haemodynamic compromise) may be discharged directly from the emergency department after stable sinus rhythm is restored.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Admission to hospital is indicated for the following patient groups:
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Patients with underlying heart disease who have haemodynamic consequences or symptoms of angina, heart failure, or syncope or who are at risk for a complication resulting from therapy of the arrhythmia
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Older patients
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Associated or precipitant medical conditions that require further treatment, such as heart failure, pulmonary problems (e.g., pneumonia, pulmonary embolism), hypertension, or hyperthyroidism.
                        </p>
                     </li>
                  </ul>
               </section>
               <section>
                  <h3>Haemodynamically unstable AF</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     AF with a rapid ventricular rate causing ongoing chest pain, hypotension, shortness of breath, dizziness, or syncope requires immediate DC cardioversion. This is performed under adequate short-acting general anaesthesia and involves delivery of an electrical shock synchronised with the intrinsic activity of the heart by sensing the R wave of the ECG (i.e., synchronised). The energy output for successful termination of new-onset AF varies from 200 J to a maximum of 400 J depending on the body size and the presence of other co-morbid conditions. Lower energy of 100 J may be used as the starting level when biphasic energy is used.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     For patients with haemodynamically unstable AF, initiation of anticoagulation should not delay DC cardioversion. It is reasonable to consider administering intravenous bolus of unfractionated heparin followed by infusion, or low molecular weight heparin or DOAC and to continue this after cardioversion unless contraindicated.
                     <span class="reference">
                        <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                        <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                           http://content.onlinejacc.org/article.aspx?articleid
                           <rc-c2d-number data-rc-number="=1854231
                              ">=1854231</rc-c2d-number>
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                        </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Haemodynamically stable AF: symptomatic</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Patients require rate-control therapy until cardioversion is successful. If there is no evidence of heart failure, beta-blockers (intravenous esmolol, propranolol, metoprolol tartrate, or oral atenolol, metoprolol succinate, nadolol, propranolol, bisoprolol, carvedilol) or non-dihydropyridine calcium-channel blockers (diltiazem, verapamil) are the preferred choice. If rate control is inadequate with monotherapy, a combination of a beta-blocker and calcium-channel blockers may be used. Patient should be carefully monitored to prevent excess AV nodal blockade.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circ.ahajournals.org/content/123/10/e269.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21382897?tool=bestpractice.com
                     </span>
                     </span>
                     If there is evidence of heart failure, certain drugs such as calcium-channel blockers, and most anti-arrhythmic drugs except digoxin 
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_1" name="evidence-score-1" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#popuplink-ref-score_1" data-original-title="">
                        Evidence B
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Control of heart rate in haemodynamically stable acute-onset AF: there is medium-quality evidence that, compared with placebo, digoxin was more effective at controlling heart rate at 30 minutes to 2 hours in people with AF lasting up to 7 days.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Randomized controlled trials (RCTs) of &lt;200 participants, methodologically flawed RCTs of &gt;200 participants, methodologically flawed systematic reviews (SRs) or good quality observational (cohort) studies.
                        </span>
                     </span>
                     or amiodarone, 
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_2" name="evidence-score-2" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#popuplink-ref-score_2" data-original-title="">
                        Evidence C
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Control of heart rate in haemodynamically stable acute-onset AF: there is poor-quality evidence that, compared with digoxin, amiodarone may be as effective at controlling heart rate at 30 minutes.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Poor quality observational (cohort) studies or methodologically flawed randomized controlled trials (RCTs) of &lt;200 participants. 
                        </span>
                     </span>
                     should not be used. Digoxin is the preferred drug for rate control in patients with AF and heart failure. Amiodarone has multiclass (I to IV) anti-arrhythmic properties, and can be used for rate control in heart failure patients only if digoxin is contraindicated
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Dronedarone, a multichannel blocker with non-competitive anti-adrenergic activity, is similar to amiodarone but less effective.
                     <span class="reference"> 
                     <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                     <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference">
                        <a href="#referencePop52" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[52]</a> 
                        <span class="citationText" aria-hidden="true">
                           Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54
                           <rc-c2d-number data-rc-number=":1089-1095">:1089-1095</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19744618?tool=bestpractice.com
                        </span>
                     </span>
                     It is approved in Europe for the maintenance of sinus rhythm after successful cardioversion in clinically stable adult patients with paroxysmal or persistent AF and associated cardiovascular risk factors. It can be used in patients with NYHA class I or II heart failure, but is contraindicated in those with NYHA class IV heart failure or NYHA class II-III heart failure with a recent decompensation requiring admission to hospital or referral to a specialised heart failure clinic. It is also contraindicated in patients with permanent AF.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Patients presenting with new-onset AF of &lt;48 hours' duration and no evidence of LA thrombus on TOE should have DC
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_3" name="evidence-score-3" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#popuplink-ref-score_3" data-original-title="">
                        Evidence A
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Conversion to sinus rhythm in haemodynamically stable acute-onset AF: there is good-quality evidence that electrical cardioversion is more effective than intravenous propafenone at increasing the proportion of patients who convert to sinus rhythm within 6 hours in those with haemodynamically stable new-onset AF of &lt;48 hours duration. Consensus is that it should be used in those with haemodynamically unstable new-onset AF.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Systematic reviews (SRs) or randomized controlled trials (RCTs) of &gt;200 participants.
                        </span>
                     </span>
                     or pharmacological cardioversion. DC cardioversion is fast, safe, and efficient. Pharmacological cardioversion is accomplished with the use of anti-arrhythmic agents.
                     <span class="reference"> 
                     <a href="#referencePop53" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[53]</a> 
                     <span class="citationText" aria-hidden="true">Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic review. Scand Cardiovasc J Suppl. 2013;47:2-10.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/23067130?tool=bestpractice.com
                     </span>
                     </span>
                     However, these must be used with caution as they may cause bradycardia or tachyarrhythmias.
                     <span class="reference"> 
                     <a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                     [ <img src="../images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                     </a>
                     <span class="ccaTitle" aria-hidden="true">What are the benefits and harms of antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation?</span>
                     <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1887/full</span>
                     <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                     </span>
                     Anti-arrhythmic agents with variable, but demonstrated, efficacy for cardioversion of new-onset AF include flecainide,
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_4" name="evidence-score-4" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#popuplink-ref-score_4" data-original-title="">
                        Evidence B
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Conversion to sinus rhythm in haemodynamically stable acute-onset AF: there is medium-quality evidence that, compared with placebo, oral or intravenous flecainide was more effective at increasing the rate of conversion to sinus rhythm at 1 to 24 hours in people with new-onset AF. There is poor-quality evidence that oral or intravenous flecainide may be more effective than intravenous amiodarone at increasing conversion rates to sinus rhythm at 1 to 12 hours. There is poor-quality evidence that oral or intravenous flecainide may be as effective as oral or intravenous propafenone at conversion to sinus rhythm at 1 to 12 hours.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Randomized controlled trials (RCTs) of &lt;200 participants, methodologically flawed RCTs of &gt;200 participants, methodologically flawed systematic reviews (SRs) or good quality observational (cohort) studies.
                        </span>
                     </span>
                     propafenone,
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_5" name="evidence-score-5" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#popuplink-ref-score_5" data-original-title="">
                        Evidence A
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Conversion to sinus rhythm in haemodynamically stable acute-onset AF: there is good-quality evidence that, compared with placebo, oral or intravenous propafenone was more effective at increasing the proportion of patients who convert to sinus rhythm within 24 hours in those with new-onset AF. There is poor-quality evidence that intravenous propafenone may be as effective as intravenous digoxin at increasing conversion to sinus rhythm at 1 hour. There is also poor-quality evidence that oral or intravenous propafenone may be as effective as oral or intravenous flecainide at increasing conversion to sinus rhythm at 1 to 12 hours. Compared with amiodarone, it is not known in the poor-quality evidence available whether propafenone is more or less effective at increasing conversion to sinus rhythm at 1 to 48 hours in patients with new-onset AF. Adverse effects: propafenone and flecainide are not used in patients with known or suspected ischaemic heart disease, because these drugs may cause arrhythmias.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Systematic reviews (SRs) or randomized controlled trials (RCTs) of &gt;200 participants.
                        </span>
                     </span>
                     ibutilide, vernakalant,
                     <span class="reference">
                        <a href="#referencePop54" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[54]</a> 
                        <span class="citationText" aria-hidden="true">
                           Roy D, Pratt CM, Torp-Pedersen C, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117
                           <rc-c2d-number data-rc-number=":1518-1525">:1518-1525</rc-c2d-number>
                           .
                        </span>
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://circ.ahajournals.org/cgi/content/full/117/12/1518
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/18332267?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop55" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[55]</a> 
                     <span class="citationText" aria-hidden="true">Kowey PR, Dorian P, Mitchell LB, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652-659.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circep.ahajournals.org/content/2/6/652.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/19948506?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop56" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[56]</a> 
                     <span class="citationText" aria-hidden="true">Camm AJ, Capucci A, Hohnloser SH, et al; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313-321.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21232669?tool=bestpractice.com
                     </span>
                     </span>
                     dronedarone,
                     <span class="reference"> 
                     <a href="#referencePop37" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[37]</a> 
                     <span class="citationText" aria-hidden="true">Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.nejm.org/doi/full/10.1056/NEJMoa054686#t=article
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/17804843?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop38" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[38]</a> 
                     <span class="citationText" aria-hidden="true">Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/20384650?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop39" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[39]</a> 
                     <span class="citationText" aria-hidden="true">Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/19213680?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop40" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[40]</a> 
                     <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Dronedarone for the treatment of non-permanent atrial fibrillation. August 2010. http://www.nice.org.uk (last accessed 8 January 2016).</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://guidance.nice.org.uk/ta197
                     </span>
                     </span>
                     and amiodarone.
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_6" name="evidence-score-6" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#popuplink-ref-score_6" data-original-title="">
                        Evidence C
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Conversion to sinus rhythm in haemodynamically stable acute-onset AF: there is poor-quality evidence that, compared with placebo, amiodarone may be more effective at increasing conversion to sinus rhythm at 1 to 8 hours in patients with new-onset AF who are haemodynamically stable. When compared with digoxin, amiodarone may be as effective at increasing conversion to sinus rhythm at 1 to 48 hours. Compared with sotalol, amiodarone may be as effective at increasing conversion to sinus rhythm at 3 hours. Compared with flecainide, intravenous amiodarone may be less effective than oral or intravenous flecainide at increasing conversion to sinus rhythm at 1 to 12 hours. Compared with propafenone, it is not known whether amiodarone is more or less effective than propafenone at increasing conversion to sinus rhythm at 1 to 48 hours in patients with new-onset AF. Adverse effects: amiodarone is associated with adverse effects, including bradycardia and hypotension.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Poor quality observational (cohort) studies or methodologically flawed randomized controlled trials (RCTs) of &lt;200 participants. 
                        </span>
                     </span>
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_7" name="evidence-score-7" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#popuplink-ref-score_7" data-original-title="">
                        Evidence B
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Conversion to sinus rhythm in haemodynamically stable acute-onset AF: there is medium-quality evidence that, compared with verapamil, amiodarone was more effective at increasing conversion to sinus rhythm at 3 hours.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Randomized controlled trials (RCTs) of &lt;200 participants, methodologically flawed RCTs of &gt;200 participants, methodologically flawed systematic reviews (SRs) or good quality observational (cohort) studies.
                        </span>
                     </span>
                     Class III agents (including amiodarone and ibutilide) are less efficacious than class IC agents (flecainide and propafenone) in conversion to sinus rhythm.
                     <span class="reference">
                        <a href="#referencePop57" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[57]</a> 
                        <span class="citationText" aria-hidden="true">
                           Kochiadakis GE, Igoumenidis NE, Hamilos ME, et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007;99
                           <rc-c2d-number data-rc-number=":1721-1725">:1721-1725</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/17560882?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop58" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[58]</a> 
                     <span class="citationText" aria-hidden="true">Xanthos T, Bassiakou E, Vlachos IS, et al. Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. Int J Cardiol. 2007;121:291-295.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/17434635?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference"> 
                     <a href="#referencePop59" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[59]</a> 
                     <span class="citationText" aria-hidden="true">Xanthos T, Prapa V, Papadimitriou D, et al. Comparative study of intravenous amiodarone and procainamide in the treatment of atrial fibrillation of recent onset. Minerva Cardioangiol. 2007;55:433-441.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/17653020?tool=bestpractice.com
                     </span>
                     </span>
                     Intravenous vernakalant has demonstrated superior efficacy to amiodarone for acute conversion of recent-onset AF.
                     <span class="reference"> 
                     <a href="#referencePop56" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[56]</a> 
                     <span class="citationText" aria-hidden="true">Camm AJ, Capucci A, Hohnloser SH, et al; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313-321.</span> 
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21232669?tool=bestpractice.com
                     </span>
                     </span>
                     Oral vernakalant appears to be effective in preventing AF recurrence post-cardioversion.
                     <span class="reference"> 
                     <a href="#referencePop60" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[60]</a> 
                     <span class="citationText" aria-hidden="true">Torp-Pedersen C, Raev DH, Dickinson G, et al. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol. 2011;4:637-643.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circep.ahajournals.org/content/4/5/637.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21841207?tool=bestpractice.com
                     </span>
                     </span>
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     The strategy for managing anticoagulation in patients presenting with new-onset AF of &lt;48 hours' duration and with no evidence of LA thrombus is as follows:
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           If CHA2DS2-VASc score is 0-1, no anticoagulation is required.
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           If CHA2DS2-VASc score is ≥2, intravenous heparin (aPTT of 45-60 seconds) or subcutaneous low molecular weight heparin should be started before cardioversion. Once sinus rhythm is restored, the patients should be started on warfarin and heparin continued until the warfarin levels are therapeutic (INR 2-3). In selected patients warfarin may be replaced with a DOAC such as dabigatran, rivaroxaban, apixaban, or edoxaban.
                           <span class="reference">
                              <a href="#referencePop61" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[61]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126
                                 <rc-c2d-number data-rc-number=":2381-2391">:2381-2391</rc-c2d-number>
                                 .
                              </span>
                              <span class="citationFullTextUrl" aria-hidden="true">
                              http://circ.ahajournals.org/content/126/20/2381.long
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/23071159?tool=bestpractice.com
                              </span>
                           </span>
                           DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency. The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated. 
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Anticoagulation is continued for at least 4 weeks after cardioversion, and may be required for longer in some patients.
                           <span class="reference">
                              <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                              <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://content.onlinejacc.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1854231
                                    ">=1854231</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference">
                              <a href="#referencePop62" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[62]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Sorino M, Colonna P, De Luca L, et al. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). J Cardiovasc Med (Hagerstown). 2007;8
                                 <rc-c2d-number data-rc-number=":1034-1042">:1034-1042</rc-c2d-number>
                                 .
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/18163016?tool=bestpractice.com
                              </span>
                           </span>
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     If the onset of symptoms is &gt;48 hours or unknown and there is no evidence of LA thrombus on TOE, patients should have DC
                     <!-- TODO might need to give a proper name for this class as to hide the span elements  -->
                     <span class="reference">
                        <a data-trigger="click focus" data-toggle="popover" class="evidenceScorePop" title="" id="popuplink-ref-score_3" name="evidence-score-3" href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#popuplink-ref-score_3" data-original-title="">
                        Evidence A
                        </a>
                        <span class="esContent" aria-hidden="true">
                           <!-- don't use para.html here as <span> doesn't allow to contain <p> -->
                           Conversion to sinus rhythm in haemodynamically stable acute-onset AF: there is good-quality evidence that electrical cardioversion is more effective than intravenous propafenone at increasing the proportion of patients who convert to sinus rhythm within 6 hours in those with haemodynamically stable new-onset AF of &lt;48 hours duration. Consensus is that it should be used in those with haemodynamically unstable new-onset AF.
                        </span>
                        <span class="esInfo" aria-hidden="true">
                        Systematic reviews (SRs) or randomized controlled trials (RCTs) of &gt;200 participants.
                        </span>
                     </span>
                     or pharmacological cardioversion, but the cardioversion should not be attempted until the patient is established on anticoagulation. CHA2DS2-VASc score also predicts risk of cardiovascular complications post cardioversion.
                     <span class="reference">
                        <a href="#referencePop63" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[63]</a> 
                        <span class="citationText" aria-hidden="true">
                           Grönberg T, Hartikainen JE, Nuotio I, et al. Anticoagulation, CHA2DS2VASc score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV study). Am J Cardiol. 2016;117
                           <rc-c2d-number data-rc-number=":1294-1298">:1294-1298</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/26892448?tool=bestpractice.com
                        </span>
                     </span>
                     The strategy for managing anticoagulation in these patients is as follows:
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           If CHA2DS2-VASc score is 0-1, heparin should be started, and cardioversion should be delayed until the patient is established on heparin with a target activated partial thromboplastin time of 45 to 60 seconds. Following successful cardioversion, heparin can be discontinued. The decision to administer aspirin for long-term therapy in these patients should be individualised and discussed with the patient as no major consensus exists for those with a CHADS2 score of 1, or a CHA2DS2-VASc score of 1 due to sex risk (i.e., female patients).
                           <span class="reference">
                              <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                              <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://content.onlinejacc.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1854231
                                    ">=1854231</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop10" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[10]</a> 
                           <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Atrial fibrillation: management. 2014. https://www.nice.org.uk/guidance/cg180 (last accessed 8 January 2016).</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://www.nice.org.uk/guidance/cg180/resources/atrial-fibrillation-management-35109805981381
                           </span>
                           </span>
                           <span class="reference">
                              <a href="#referencePop64" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[64]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Lip GY, Skjøth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65
                                 <rc-c2d-number data-rc-number=":1385-1394">:1385-1394</rc-c2d-number>
                                 .
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/25770314?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop65" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[65]</a> 
                           <span class="citationText" aria-hidden="true">Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-642.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25677422?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference">
                              <a href="#referencePop66" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[66]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Joundi RA, Cipriano LE, Sposato LA, et al. Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: systematic review and meta-analysis. Stroke. 2016;47
                                 <rc-c2d-number data-rc-number=":1364-1367">:1364-1367</rc-c2d-number>
                                 .
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/27026630?tool=bestpractice.com
                              </span>
                           </span>
                           AHA 2014 guidelines include aspirin as an option in this circumstance, while National Institute for Health and Care Excellence and European Society of Cardiology guidelines do not recommend aspirin.
                           <span class="reference">
                              <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                              <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://content.onlinejacc.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1854231
                                    ">=1854231</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference">
                              <a href="#referencePop3" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[3]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18
                                 <rc-c2d-number data-rc-number=":1609-1678">:1609-1678</rc-c2d-number>
                                 .
                              </span>
                              <span class="citationFullTextUrl" aria-hidden="true">
                              http://eurheartj.oxfordjournals.org/content/37/38/2893
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/27567465?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop10" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[10]</a> 
                           <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Atrial fibrillation: management. 2014. https://www.nice.org.uk/guidance/cg180 (last accessed 8 January 2016).</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://www.nice.org.uk/guidance/cg180/resources/atrial-fibrillation-management-35109805981381
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           If CHA2DS2-VASc score is ≥2, concomitant heparin and warfarin therapy should be started, and heparin continued until the warfarin levels are therapeutic (INR 2-3).
                           <span class="reference">
                              <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                              <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://content.onlinejacc.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1854231
                                    ">=1854231</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop22" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[22]</a> 
                           <span class="citationText" aria-hidden="true">Peters NS, Schilling RJ, Kanagaratnam P, et al. Atrial fibrillation: strategies to control, combat, and cure. Lancet. 2002; 359;593-603.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/11867130?tool=bestpractice.com
                           </span>
                           </span>
                           Anticoagulation with warfarin at the target INR should be established for 3 to 4 weeks before cardioversion is attempted.
                           <span class="reference"> 
                           <a href="#referencePop22" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[22]</a> 
                           <span class="citationText" aria-hidden="true">Peters NS, Schilling RJ, Kanagaratnam P, et al. Atrial fibrillation: strategies to control, combat, and cure. Lancet. 2002; 359;593-603.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/11867130?tool=bestpractice.com
                           </span>
                           </span>
                           Warfarin may be replaced with a DOAC (e.g., dabigatran, rivaroxaban, apixaban, or edoxaban) in selected patients such as those in whom low and ineffective TTR of warfarin can be predicted (i.e., using the SAMe-TT(2)R(2) scoring system), or those who refuse to take warfarin.
                           <span class="reference">
                              <a href="#referencePop50" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[50]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014;127
                                 <rc-c2d-number data-rc-number=":1083-1088">:1083-1088</rc-c2d-number>
                                 .
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/24858062?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference">
                              <a href="#referencePop51" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[51]</a> 
                              <span class="citationText" aria-hidden="true">Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014;146:719-726.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://journal.publications.chestnet.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1860569
                                    ">=1860569</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/24722973?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference">
                              <a href="#referencePop61" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[61]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126
                                 <rc-c2d-number data-rc-number=":2381-2391">:2381-2391</rc-c2d-number>
                                 .
                              </span>
                              <span class="citationFullTextUrl" aria-hidden="true">
                              http://circ.ahajournals.org/content/126/20/2381.long
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/23071159?tool=bestpractice.com
                              </span>
                           </span>
                           DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency. The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated. 
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Anticoagulation is continued for at least 4 weeks after cardioversion, and may be required for longer in some patients.
                           <span class="reference">
                              <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                              <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://content.onlinejacc.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1854231
                                    ">=1854231</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference">
                              <a href="#referencePop62" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[62]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Sorino M, Colonna P, De Luca L, et al. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). J Cardiovasc Med (Hagerstown). 2007;8
                                 <rc-c2d-number data-rc-number=":1034-1042">:1034-1042</rc-c2d-number>
                                 .
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/18163016?tool=bestpractice.com
                              </span>
                           </span>
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     If there is evidence of LA thrombus on TOE, concomitant heparin and warfarin therapy should be started, and heparin continued until the warfarin levels are therapeutic (INR 2-3). Anticoagulation with warfarin at the target INR should be established for 3 to 4 weeks before cardioversion is attempted. Furthermore, a repeat TEE to assess for LA thrombus should be carried out before cardioversion is considered. DOACs such as dabigatran, rivaroxaban, apixaban, and edoxaban may be used as an alternative to warfarin and are associated with an overall increase in clinical benefit compared with warfarin.
                     <span class="reference">
                        <a href="#referencePop61" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[61]</a> 
                        <span class="citationText" aria-hidden="true">
                           Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126
                           <rc-c2d-number data-rc-number=":2381-2391">:2381-2391</rc-c2d-number>
                           .
                        </span>
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://circ.ahajournals.org/content/126/20/2381.long
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23071159?tool=bestpractice.com
                        </span>
                     </span>
                     DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency. The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated. Anticoagulation is continued for at least 4 weeks after cardioversion, and may be required for longer in some patients.
                     <span class="reference">
                        <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                        <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                           http://content.onlinejacc.org/article.aspx?articleid
                           <rc-c2d-number data-rc-number="=1854231
                              ">=1854231</rc-c2d-number>
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                        </span>
                     </span>
                     <span class="reference">
                        <a href="#referencePop62" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[62]</a> 
                        <span class="citationText" aria-hidden="true">
                           Sorino M, Colonna P, De Luca L, et al. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). J Cardiovasc Med (Hagerstown). 2007;8
                           <rc-c2d-number data-rc-number=":1034-1042">:1034-1042</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/18163016?tool=bestpractice.com
                        </span>
                     </span>
                  </p>
               </section>
               <section>
                  <h3>Haemodynamically stable AF: asymptomatic</h3>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Patients with CHA2DS2-VASc score 0-1 can be observed. Most cases of new-onset AF revert to sinus rhythm spontaneously, usually in the first 24 hours. If AF does not resolve spontaneously, rate-control therapy is required until cardioversion is successful. Cardioversion may be attempted without the need for anticoagulation.
                  </p>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Patients with a CHA2DS2-VASc score ≥2 require immediate anticoagulation. Concomitant heparin and warfarin therapy should be started, and heparin continued until the warfarin levels are therapeutic (INR 2-3). In selected patients warfarin may be replaced with a DOAC such as dabigatran, rivaroxaban, apixaban, or edoxaban.
                     <span class="reference">
                        <a href="#referencePop61" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[61]</a> 
                        <span class="citationText" aria-hidden="true">
                           Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126
                           <rc-c2d-number data-rc-number=":2381-2391">:2381-2391</rc-c2d-number>
                           .
                        </span>
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://circ.ahajournals.org/content/126/20/2381.long
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23071159?tool=bestpractice.com
                        </span>
                     </span>
                     DOACs should not be used in patients with mechanical prosthetic valves. Dabigatran should not be used in patients with marked renal insufficiency. The concomitant use of DOACs with heparin (including low molecular weight heparin), heparin derivatives, or warfarin is contraindicated. Patients should be observed to see whether AF resolves spontaneously. If AF does not resolve, anticoagulation with warfarin at the target INR should be established for 3 to 4 weeks before cardioversion is attempted. Rate-control therapy is required until cardioversion is performed. Anticoagulation is continued for at least 4 weeks after cardioversion. 
                  </p>
               </section>
               <section>
                  <h3>Post-cardioversion management</h3>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Patients with a newly detected first episode of new-onset AF converted to sinus rhythm are not continued on rhythm maintenance therapy as the risks outweigh the benefits.
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           The decision to administer aspirin for long-term therapy should be individualised and discussed with the patient, as no major consensus exists for those with a CHADS2 score of 1 or a CHA2DS2-VASc score of 1 due to sex risk (i.e., female patients).
                           <span class="reference">
                              <a href="#referencePop2" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[2]</a> 
                              <span class="citationText" aria-hidden="true">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://content.onlinejacc.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1854231
                                    ">=1854231</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/24685669?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop10" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[10]</a> 
                           <span class="citationText" aria-hidden="true">National Institute for Health and Care Excellence. Atrial fibrillation: management. 2014. https://www.nice.org.uk/guidance/cg180 (last accessed 8 January 2016).</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           https://www.nice.org.uk/guidance/cg180/resources/atrial-fibrillation-management-35109805981381
                           </span>
                           </span>
                           <span class="reference">
                              <a href="#referencePop64" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[64]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Lip GY, Skjøth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65
                                 <rc-c2d-number data-rc-number=":1385-1394">:1385-1394</rc-c2d-number>
                                 .
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/25770314?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop65" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[65]</a> 
                           <span class="citationText" aria-hidden="true">Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-642.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25677422?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                  </ul>
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Long-term anticoagulation is required for patients with identified high risk for thromboembolism even after sinus rhythm has been restored.
                     <span class="reference"> 
                     <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                     <span class="citationText" aria-hidden="true">Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367.</span> 
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://circ.ahajournals.org/content/123/10/e269.long
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/21382897?tool=bestpractice.com
                     </span>
                     </span>
                     <span class="reference">
                        <a href="#referencePop62" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[62]</a> 
                        <span class="citationText" aria-hidden="true">
                           Sorino M, Colonna P, De Luca L, et al. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). J Cardiovasc Med (Hagerstown). 2007;8
                           <rc-c2d-number data-rc-number=":1034-1042">:1034-1042</rc-c2d-number>
                           .
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/18163016?tool=bestpractice.com
                        </span>
                     </span>
                  </p>
               </section>
            </div>
         </div>
         <div class="card-block disclaimer">
            <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">disclaimer</a> </span></p>
         </div>
      </main>
      <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
      <script>
         /*<![CDATA[*/
         
         var messagesCountryCode = "en_GB";
         /*]]>*/
           
      </script>
      <aside id="panel-nhs" class="card-block">
         <div id="access" class="col-sm-6">
            <div class="row">
               <div class="col-md-6">
                  <p>Access provided by:</p>
               </div>
               <div class="col-md-6">
                  <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
               </div>
            </div>
         </div>
      </aside>
      <footer id="footer">
         <div class="container">
            <div class="row">
               <nav class="col-md-9" role="navigation">
                  <div class="row">
                     <dl class="col-md-4" role="menu">
                        <dt>Browse</dt>
                        <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                     </dl>
                     <!-- logged-in individual or institutional user -->
                     <!-- unknown user -->
                     <!--institutional user not logged in-->
                     <dl class="col-md-4" role="menu">
                        <dt>Services</dt>
                        <dd><a href="https://bestpractice.bmj.com/login">Log in</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/registration">Create an account</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/" target="_blank">About us</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/app/" target="_blank">Mobile app</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></dd>
                        <dd>
                           <a href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                           </a>
                        </dd>
                     </dl>
                     <dl class="col-md-4" role="menu">
                        <dt>Legal</dt>
                        <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                        <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and conditions</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie policy</a></dd>
                     </dl>
                  </div>
                  <!-- row -->
               </nav>
               <div class="col-md-3">
                  <ul>
                     <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo" title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo" title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo" title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a></li>
                  </ul>
                  <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
                  <p class="issn">
                     <small>
                        ISSN
                        <rc-c2d-number data-rc-number=" 2515-9615"> 2515-9615</rc-c2d-number>
                     </small>
                  </p>
               </div>
            </div>
            <!-- row -->  
         </div>
         <!-- container -->    
      </footer>
      <div class="container modal-registration-form" aria-hidden="true">
         <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-header">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                        <div class="col-md-12">
                           <p>Please complete all fields.</p>
                        </div>
                     </div>
                  </div>
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <form id="feedbackForm" action="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#" novalidate="novalidate">
                              <div class="row">
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackName">Name</label> 
                                       <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                    </div>
                                 </div>
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackEmail">Email</label> 
                                       <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email" value="">
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <h2 id="feedbackPageTitle" class="h3">Page: New-onset atrial fibrillation - Approach | BMJ Best Practice</h2>
                                 </div>
                              </div>
                              <input id="feedbackPage" name="feedbackPage" type="hidden" value="New-onset atrial fibrillation - Approach | BMJ Best Practice">
                              <div class="row">
                                 <div class="col-md-4">
                                    <p>I have some feedback on:</p>
                                    <fieldset class="form-group" role="radiogroup">
                                       <legend>Feedback on: </legend>
                                       <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn" value="This page" checked="checked">&nbsp;This page</label>
                                       <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn" value="This website">&nbsp;The website in general</label>
                                       <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn" value="Something else">&nbsp;Something else</label>
                                    </fieldset>
                                 </div>
                                 <div class="col-md-8">
                                    <div class="form-group floating-label textarea">
                                       <label for="feedbackContent">I have some feedback on:</label>
                                       <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <p>We will respond to all feedback.</p>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                    </button>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-12">
                                    <p>For any urgent enquiries please contact our customer services team who are ready to help with any problems.</p>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-3">
                                    <p>
                                       <b>Phone:</b> 
                                       <rc-c2d-number data-rc-number="+44 (0) 207 111 1105">+44 (0) 207 111 1105</rc-c2d-number>
                                    </p>
                                 </div>
                                 <div class="col-md-3">
                                    <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                                 </div>
                              </div>
                           </form>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Thank you</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                     </div>
                     <div class="row">
                        <div class="col-md-12">
                           <p>Your feedback has been submitted successfully.</p>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedBackBtn">
            <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/3/management-approach#"><span class="material-icons"></span>&nbsp;FEEDBACK</a></p>
         </div>
      </div>
      <script type="text/javascript" src="../jss/common.js"></script>
      <script type="text/javascript" src="../jss/main.js"></script>
      <script>
         // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
         /*<![CDATA[*/       
         function dedupe(array) {
           var seen = {};
           return array.filter(function(item) {
               return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
           });
         }
         function TopicViewed(id, title, lang) {
           this.id = id;
           this.title = title;
           this.lang = lang;
         }
         jQuery(document).ready(function() {
           var topicId = 3;
           var topicLang = "en-gb";
           var topicTitle = "New-onset atrial fibrillation";
           if(topicId){
               
             var topicsViewed = [];
             if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
             }
               
             topicsViewed.unshift(new TopicViewed(topicId, topicTitle, topicLang));// Add new topics at the beginning
             topicsViewed = dedupe(topicsViewed);// Remove duplicates
             if (topicsViewed.length > 15){// Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0,14);  
             }
         
             localStorage.topicsViewed = JSON.stringify(topicsViewed);
           }
          });       
         /*]]>*/
      </script>
      <script type="text/javascript">
         _linkedin_data_partner_id = "103646";
      </script>
      <script type="text/javascript">
         (function()
         {var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);}
         )();
      </script>
      <script type="text/javascript" data-cfasync="false">
         (function(W,i,s,e,P,o,p){W['WisePopsObject']=P;W[P]=W[P]||function()
         { (W[P].q=W[P].q||[]).push(arguments)}
         ,W[P].l=1*new Date();o=i.createElement(s),
         p=i.getElementsByTagName(s)[0];o.async=1;o.src=e;p.parentNode.insertBefore(o,p)
         })(window,document,'script','//loader.wisepops.com/get-loader.js?v=1&site=qudyiEfMBd','wisepops');
         window.WisePopsLoaderCallback = function(wisepops) {
                         wisepops._storage.visits = wisepops._storage.visits.slice(0, 2);
                         wisepops._storage._saveVisits();
                       };
      </script>
      <noscript>
         <img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=103646&fmt=gif" />
      </noscript>
      <!--[if lte IE 7]><script>var isIE7OrOlder = true; </script><![endif]-->   
      <!--[if lte IE 9]><script type="text/javascript" src="/gzip_e7393341757851d76c3264b590cf5143/js/browserupdate.js" ></script>
      <![endif]-->
      <script src="../jss/adsct.js" type="text/javascript"></script><script type="text/javascript" id="createCookie">(function(){var b="bestpractice.bmj.com\/topics\/en-gb\/3\/management-approach",a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};a("RefTrack",b,2);a("RefTrackGroup","bestpractice.bmj.com",2)})();</script><script type="text/javascript" id="copyText">function getSelectionText(){var a="";window.getSelection?a=window.getSelection().toString():document.selection&&"Control"!=document.selection.type&&(a=document.selection.createRange().text);return a}document.addEventListener("copy",function(a){dataLayer.push({event:"textCopied",clipboardText:getSelectionText(),clipboardLength:getSelectionText().length})});</script>
      <script type="text/javascript" id="facebookPixel">!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init","414393182248444");fbq("track","PageView");</script>
      <noscript><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=414393182248444&amp;ev=PageView&amp;noscript=1"></noscript>
      <button id="scrollTop" class="material-scrolltop" type="button"><span class="material-icons"></span></button>
      <rc-c2d-menu class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF">
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05">
            <img class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAFgAAABYCAYAAABxlTA0AAAAAXNSR0IArs4c6QAAB99JREFUeAHtnWtsVEUUx/+73T4ohUpBXgVKyysgGATFokIJUdCYEJD4waghBD4AfvAFNEbwFaM8DAmJiSbiAzTB+AECGgiEoAQiLwFJ5FlKodBSHi2U0kK77dY5S5e2S/feOXPvsC13TrLZvXfOnJnzu3PnzuvO+hAljSuRjRBmoRETRFAOfOguvlPEcWKUqjmUIOCL6DQ2wo+VWCJAfiQ+CZHz5tsZgTDgMNzl2CxMvezMnIkdTcAfPkEl18CNZuPKsa+pzi0w1YIrPO8z4m96oJk69z407pzwi5JLrQUjmghQHZyjybYxKwj4m9q5BoYmAlSCUzTZNmYFAaqDTQ9NY1EIaLMdSAUG5AF9xwMZw4AumUDnXkBSFyAxDUhIEpdXNF58d5vi2vLRGAJCDUBDHRC8BdRVAdWXgaoSoOIUULoXKN4F1NdoyYL7gLOnAmPfBrImA4FkLZlmGaULmEAfcaMmdb57kbsNbm2ivhY4vxM4tBoo2tY6zOGRr3GZqCTckD7jgCnfAL3HuGEtfjbKDgPb5wOXDriSBxfuT2EibznwprjVOjpcQko+kC/kk3hEORVnFqiefWUjkLtYf13q1FNOfKpWyCfyjXx0IA4Ai6jT1gNDpjlIvp1HJd/IRwclWR1w3pcPN9zItSfI5KuiqAGmB9rTCxWT7IDRyFfyWUHUAFNrQXf7VcEZbVHIV/JZQfiAqZ37MLQWuLDIZ/KdKXzA1Inwqij4zuvJUZOFemgSQr2XNYdL8euxMhy/Wo2K20GJWPpUEkVvLrNLMvKyuuHd3P4Y3kP06rgS7p0KBoxuNQ8wjS1IdH8Lr9/G3N9P4O8LN7guaNMPNoRw7sbt8Icu+tKJ2Xg/Nwv+e/PqEkmT78Tg7FYJ5bsqvCqCBm5s5HJ1HZ778Z92BTc6y7X1ISzZWYjFOwqig+yPJRi0NMIDTKNiNrJgy8m4Vwc2WbwX/PXBi9jDvcskGNxLQPzgAaYhRwvZee46/jh9zUKjfQU1igUh721nlmIbBtEe8gDTeK6FdCS4ETeOllWhpEoMV8qKDYNoMzzASV2j47c6LhIPkY4orHzThAFDeIATrZs2t+rEzEEHFFa+aTaGITzANM3jdWEy4AGmOTSvC5MBD7CXBnhiFSQmA15PLlaiCucnii7rvLHWzT4Fs+EotaLXNnvTcdXorsaLG+Cs9BTMHN7TVWcixqqD7edhy6siIh6Yb2kCBrA0KjVFA1iNm3QsA1galZqiAazGTTqWASyNSk3RAFbjJh3LAJZGpaZoAKtxk44Vt56cdA5bKG45U45Np662ONP2z2CDOyty27bOO9uhAB+9XIWf/i3leSih3Smgb5TQVBHiAvRPF9PxmsTzgDO7JiP7kU6a8HJnlbVlI36GXx/ZR7wqqE88XYJ7pyVj0TNZ+ugKy54FnCTWqq2dPgJdk/U94OjKeRJwekoA62eOxCQxq6JbOlQzzQ0Yuf3SsW76Y6AZlQchcQMcDPE7A8n0QqGiDM5Ixfwn+4lPJhJ8Oh9rrTMYN8CVd+pb50TiiObwfjhSioKKGgntZpVfZozEqyP0zP81p9L2L/Ui0YY9Tgm7oQCYbuv/5udi/5xxYl2vfCmkBeDxEh5gerHaQjhPZNZ6sKg0R/dOw+zRfaPOxj5cfaAYV6qDsRU0hvAA01vrFjKQ0SMqu1WLCzcZqxqj0v10Ug6oNSAj1WLN3Oe7i2RUXdfhAaYtASzk8V68hXEHS29aWLMOejQ1ER9OyLZWahH6fbjufvCrP3mAab8FC5k8MAM+Rt2472KlhTX7oLdEq2Bod7l3ietDISz9s9DeqMsaPMC0mYWF9OyciFE95UvxxpNXLKzZBwXEGywrnh9ir9ikQentK3F2UaUTa1LkAaadQmxk6qAMG43m4OLKO/jr/PXmEwq/XhrcHVMH0f6lcpK/44ycoktaPMC0DYuNzBO3LfXzZWXV3mJZ1Zh6K18YgoBfLk2qljactJ8ViZkYM0AuVxGjtMeNjfQTL/vNeUK+CbWtsByHL1lXPTZJYpiohxc8Jb9Sk+rieoWepF0+2grnAaYNhCQk/9mBSGFMw7yz/bSEVWuVJaJF0SNVbgX+GdET/PaQ/d1onaJcKA9weHcm+7Zrn7Sk8JuUclkA9ovbdo1oRjmR9OQAPsnLkTbxxZ4iVNbyu+vSCTQp8gDTO7q0O5OELBw/QPT/rV/7ammG3ro8cc1Zl5aqplGSbfHymiCW7TnfMgtafvMAUxZo6ytJoWHBuWMyQS9i233qxFT7GxuPoSZo3R23SpreO141ZWj4IWuXHoV/d6QExTfvWJl0HKa2rdesQ97cMyKCe7n8QBO/BFMitK+YzcBPJC9e/1YDTJu27f/K6+yk/FcDTKZ3fQAUbJZKxMtK6oDF3uTY/JqBbFN6HAAWlqnZtmEGsG+FqZNjgHYGOGxUlORd+cDP4wHaWNNIKwIuAG6yRw++tWOB314ECreK0m3f42uVk4f0QG7OheM87b9Ln5gbNIs9J2hbhAe1QTMn7zK6FbxxE7WOhkxGjE6YAP0LQXymWz1yAagO1tsZ9wjIWG7SvxCUxwo0550ToBJ81rkZYyEWAaqDd8cKNOedE/CLFcJrBWTrJTvO0/GsBb9vEYoE4M88S0Cz4+GRY/OXk/ooh7vKYrVTCPmYJqqLj0114S7s++Y+zN/+ugv4fzOpwZkATYhDAAAAAElFTkSuQmCC">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="Call with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 24 26">
                  <path fill="#0083BF" fill-rule="evenodd" stroke="#0684BD" stroke-width=".9" d="M6.656 17.651C.942 10.547.28 4.627 2.545 2.607c.592-.522 2.16-1.323 2.892-1.427.801-.14 1.602.243 2.02 1.01.802 1.636 1.777 3.238 2.788 4.805.452.697.348 1.567-.244 2.16-.349.348-.767.557-1.15.765a3.18 3.18 0 0 0-.801.523s-.105.104-.105.313c-.035.453.035 1.707 2.02 4.214 2.16 2.647 3.45 2.82 3.798 2.82.14 0 .244-.034.244-.034.244-.21.453-.453.662-.697.314-.348.593-.696 1.01-.975.697-.452 1.638-.348 2.16.21 1.325 1.323 2.753 2.576 4.112 3.76.662.557.906 1.428.557 2.16-.244.66-1.359 2.02-2.02 2.541-.558.488-1.324.697-2.195.697-3.345 0-7.7-2.925-11.637-7.8z"></path>
               </svg>
            </div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v"></div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="SMS with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 22 21">
                  <path fill="#0684BD" fill-rule="nonzero" d="M10.944.014C4.91.014.007 4.068.007 9.316c0 2.86 1.54 5.626 4.085 7.417-.094.534-.377 1.257-1.162 2.64l-.692 1.131h1.383a6.976 6.976 0 0 0 4.84-1.917c.817.157 1.634.252 2.483.252 6.034 0 10.936-4.275 10.936-9.523 0-5.28-4.902-9.302-10.936-9.302z"></path>
               </svg>
            </div>
         </div>
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO"></div>
         </div>
      </rc-c2d-menu>
      <script src="../jss/saved_resource.js" type="text/javascript"></script>
   </body>
</html>